Table 1.
Patient characteristics and laboratory data at baseline in individuals with HIV mono-infection, HIV-HBV co-infection with positive HBsAg and individuals with HIV-HBV co-infection and HBsAg loss.
| Patient characteristics and laboratory data |
HIV group (N = 111) |
HIV-HBV group (N = 62) |
HIV-HBV with HBsAg loss (N = 39) |
P -value |
|---|---|---|---|---|
| Male Gender (%) | 57 (51.4%) | 36 (58%) | 21 (53.8%) | 0.697 |
| Median Age, IQR (years) | 35 (26, 45) | 26 (25, 31) | 34 (25, 43) | <0.001 |
| Median HIV duration, IQR (years) |
12 (6, 14) | 14 (11, 14) | 9 (6, 13) | 0.003 |
| Median ART duration, IQR (years) |
9 (4, 13) | 13 (7, 13) | 5.5 (4.75, 8.5) | 0.093 |
| Median Lymphocytes, IQR (cells/μL) |
2,060 (1490, 2540) | 1,840 (1400, 2445) | 1,740 (1427, 1950) | 0.668 |
| Median Thrombocytes, IQR (cells/μL) |
2,61,500 (2,22,750, 3,0,000) | 2,13,000 (1,78,000, 2,65,750) | 2,52,000 (1,86,500, 2,71,250) | <0.001 |
| Median INR, IQR | 0.97 (0.92, 1.04) | 0.98 (0.95, 1.05) | 0.97 (0.94, 1) | 0.447 |
| Median AST, IQR (IU/L) | 24 (19, 30) | 40 (29, 51) | 25 (19, 32) | <0.001 |
| AST > ULN*, (%) | 6 (5.4%) | 8 (12.9%) | 1 (2.6%) | 0.081 |
| Median ALT, IQR (IU/L) | 28 (21, 36.25) | 51.5 (31, 66) | 29 (23, 36) | <0.001 |
| ALT > ULN*, (%) | 3 (2.7%) | 14 (22.6%) | 0 | <0.001 |
| Median ALP, IQR (IU/L) | 75 (60, 98) | 73 (62, 91) | 64.5 (58, 85.5) | 0.305 |
| Median GGT, IQR (IU/L) | 33 (17, 57) | 33 (20.5, 58) | 21 (14, 47.5) | 0.319 |
| Total bilirubin >2 mg/dl (%) | 7 (6.3%) | 1 (1.6%) | 3 (7.69%) | 0.116 |
| Median serum glucose, IQR (mg/dl) | 95 (86, 102) | 90 (84, 97) | 92 (87, 97) | 0.148 |
| Median serum Cholesterol, IQR (mg/dl) | 208 (170, 256) | 181 (152, 209) | 196 (155, 226) | 0.008 |
| Cholesterol >200 mg/dl (%) | 54 (48.6%) | 17 (27.41%) | 14 (35.89%) | 0.024 |
| Median tryglicerides, IQR (mg/dl) | 155 (96.25, 273.25) | 133 (98, 228) | 146 (83, 267) | 0.519 |
| Tryglicerides >150 mg/dl (%) | 51 (45.9%) | 22 (35.5%) | 13 (33.3%) | 0.389 |
| Median HDL-Cholesterol, IQR (mg/dl) | 47.8 (38.9, 57.8) | 44.4 (39.4, 61.4) | 45 (38, 57.2) | 0.963 |
| HDL- Cholesterol <0 mg/dl (%) |
28 (25.2%) | 14 (22.6%) | 8 (20.51%) | 0.837 |
| Median serum proteins, IQR (%) | 7.9 (7.4, 8.1) | 7.8 (7.5, 8.3) | 7.8 (7.8, -) | 0.727 |
| Median albumin, IQR (mg/dl) | 4.45 (4.66, 4.94) | 4.56 (4.39, 4.87) | 5 (4.66, 5) | 0.016 |
| Median AFP, IQR (ng/ml) | 2.3 (1.6, 2.9) | 2.3 (1.8, 4.6) | 1.7 (1.1, -) | 0.738 |
| Median plasma log10 HIV RNA, IQR (copies/ml) | 2.22 (1.31, 4.09) | 2.36 (1.3, 3.78) | 1.84 (1.3, 3.14) | 0.697 |
| Detectable plasma HIV RNA (%) | 47 (42.3%) | 31 (50%) | 17 (43.58%) | 0.663 |
| Median CD4 T cell count, IQR (cells/mm3) | 531 (238, 794) | 369 (270, 693) | 524 (270, 726) | 0.852 |
| CD4 T cell count <200 cells/mm3 (%) |
13 (11.7%) | 5 (8.1%) | 2 (5.12%) | 0.388 |
| CD4 T cell count <500 cells/mm3 (%) |
40 (36%) | 25 (40.3%) | 11 (28.2%) | 0.355 |
Continuous variables are represented using medians (IQR), while categorical variables are displayed using the number (%) of cases.
*
ULN, upper limit of normal (according to the laboratory kit and producer recommendations).